A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day.

Trial Profile

A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Jun 2012 Actual patient number 253 added as reported by ClinicalTrials.gov. (Extension trial: NCT01357993)
    • 22 Jun 2012 Status changed from recruiting to active no longer recruiting as reported by ClinicalTrials.gov. (Extension trial: NCT01357993)
    • 22 Jun 2012 Status changed from recruiting to active no longer recruiting as reported by ClinicalTrials.gov. (Extension trial: NCT01357993)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top